

## Special Issue

# Management of Osteoarthritis Pain

### Message from the Guest Editor

Osteoarthritis (OA) is the most common joint disorder with more than 500 million people (7% of the global population) being affected by the disease worldwide. Pain is the predominant symptom of OA and is what usually leads those with OA to seek medical care. Recent OA research has improved our understanding of the pathophysiology of the disease. Specifically, the identification of the TGF- $\beta$  and Wnt/ $\beta$ -catenin signaling pathways has provided hope for the discovery of a disease-modifying osteoarthritis drug. In recent years, several novel agents have emerged as potential treatment alternatives to improve pain, stiffness, and function with the possibility of altering the disease progression.

This Special Issue will focus on the current and future management of OA pain. The factors dictating the onset and progression of the disease will be reviewed, as will the current clinically approved methods for its treatment and diagnosis. We will also present research that elaborates on the current challenges and opportunities for the development and application of novel potentially disease-modifying medicines for the treatment of OA pain.

---

### Guest Editor

Dr. Leslie A. Tive

Investiga Tive, LLC, 15 Chapin Trail, White Lake, New York, NY 12786, USA

---

### Deadline for manuscript submissions

closed (20 July 2025)



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/158186](https://mdpi.com/si/158186)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://mdpi.com/journal/)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).